Verrica Pharmaceuticals Inc.
- VRCA
- NASDAQ
- Biotechnology
- Dermatology Therapeutics
- Drug-Device Combination (YCANTH)
$3.44
Today −0.15%Quote Oct 20, 2026, 02:57 PM UTC
−22.70%over the last month
Max drawdown −28.3%From 1-month high −28.3%3 months −36.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
Where the money comes from
Q2 2026 revenue $5.9M
- Product$5.1M86.4%
- License And Collaboration Revenue$800,00013.6%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
76
Founded
2013
Market value
$59.0M
Quote Oct 20
Analyst target
$9.00
+162.0% from here
Floor
$3.43
0.1% below price
Resistance
$3.82
11.2% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about VRCAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free